Li Z X, Liu Y N, Wang R, Li A M
Department of Respiratory Diseases, Second Artillery General Hospital, Beijing 100088, People's Republic of China.
Departments of Respiratory Diseases, People's Liberation Army General Hospital, Beijing 100853, People's Republic of China.
Clin Ter. 2015 Nov-Dec;166(6):e374-80. doi: 10.7417/T.2015.1903.
The aim of the current study was to analyze the susceptibility of gram-positive and -negative clinical isolates to a novel des-F(6)-quinolone (nemonoxacin) and other selected antimicrobial agents.
Minimal inhibitory concentrations (MICs) were determined by the agar plate dilution method according to NCCLs.
Nemonoxacin exhibited greater antimicrobial activity than other quinolones, such as ciprofloxacin, levofloxacin, and moxifloxacin, and other antimicrobials when tested against selected gram-positive organisms. This non-fluorinated quinolone was especially active against streptococci and staphylococci, including multi-resistant Streptococcus pneumoniae and methicillin-resistant Staphylococcus aureus (MRSA). Compared with ciprofloxacin, levofloxacin, and moxifloxacin, and other antimicrobials, nemonoxacin was not highly active against all tested gram-negative clinical isolates, with an MIC90 of 8-32 μg/mL.
Nemonoxacin has powerful antibacterial activity against gram-positive strains and has value in treating quinolone-resistant clinical isolates of MSSA, MRSA, and S. pneumoniae infections. Nemonoxacin should not be the first choice to treat gram-negative clinical isolate infections.
本研究旨在分析革兰氏阳性和阴性临床分离株对新型去氟（6）喹诺酮类药物（奈诺沙星）及其他选定抗菌药物的敏感性。
根据美国国家临床实验室标准委员会（NCCLs）的方法，采用琼脂平板稀释法测定最低抑菌浓度（MICs）。
在针对选定的革兰氏阳性菌进行测试时，奈诺沙星比其他喹诺酮类药物（如环丙沙星、左氧氟沙星和莫西沙星）以及其他抗菌药物表现出更强的抗菌活性。这种非氟化喹诺酮对链球菌和葡萄球菌尤其有效，包括多重耐药的肺炎链球菌和耐甲氧西林金黄色葡萄球菌（MRSA）。与环丙沙星、左氧氟沙星、莫西沙星及其他抗菌药物相比，奈诺沙星对所有测试的革兰氏阴性临床分离株的活性并不高，其MIC90为8 - 32μg/mL。
奈诺沙星对革兰氏阳性菌株具有强大的抗菌活性，在治疗对喹诺酮耐药的MSSA、MRSA和肺炎链球菌感染的临床分离株方面具有价值。奈诺沙星不应作为治疗革兰氏阴性临床分离株感染的首选药物。
